Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$47.60 USD
+0.34 (0.72%)
Updated May 29, 2024 04:00 PM ET
After-Market: $47.67 +0.07 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JANX 47.60 +0.34(0.72%)
Will JANX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
Other News for JANX
Google DeepMind CEO: ‘This Is the Next $100 Billion AI Business’
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Analyst Ratings For Janux Therapeutics
Buy Rating Affirmed for Janux Therapeutics with Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials
Janux Therapeutics price target raised by $13 at H.C. Wainwright, here's why